These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30197477)

  • 1. p21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation.
    Wang K; Baldwin GS; Nikfarjam M; He H
    World J Gastroenterol; 2018 Sep; 24(33):3709-3723. PubMed ID: 30197477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of p21-activated kinases in pancreatic cancer.
    Yeo D; He H; Baldwin GS; Nikfarjam M
    Pancreas; 2015 Apr; 44(3):363-9. PubMed ID: 25760284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer.
    Belli S; Pesapane A; Servetto A; Esposito D; Napolitano F; Ascione CM; Allotta A; Zambrano N; Marino FZ; Franco R; Troiani T; Formisano L; Bianco R
    Br J Cancer; 2023 Oct; 129(7):1071-1082. PubMed ID: 37568037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinoma.
    Ma Y; Nikfarjam M; He H
    Cancer Lett; 2022 Nov; 548():215868. PubMed ID: 36027997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging role of the KRAS-PDK1 axis in pancreatic cancer.
    Ferro R; Falasca M
    World J Gastroenterol; 2014 Aug; 20(31):10752-7. PubMed ID: 25152578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS as a Therapeutic Target.
    McCormick F
    Clin Cancer Res; 2015 Apr; 21(8):1797-801. PubMed ID: 25878360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS-related proteins in pancreatic cancer.
    Mann KM; Ying H; Juan J; Jenkins NA; Copeland NG
    Pharmacol Ther; 2016 Dec; 168():29-42. PubMed ID: 27595930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of p21 activated kinase enhances tumour immune response and sensitizes pancreatic cancer to gemcitabine.
    Wang K; Huynh N; Wang X; Baldwin G; Nikfarjam M; He H
    Int J Oncol; 2018 Jan; 52(1):261-269. PubMed ID: 29115428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reshaping the Tumor Microenvironment of KRASG12D Pancreatic Ductal Adenocarcinoma with Combined SOS1 and MEK Inhibition for Improved Immunotherapy Response.
    Norgard RJ; Budhani P; O'Brien SA; Xia Y; Egan JN; Flynn B; Tagore JR; Seco J; Peet GW; Mikucka A; Wasti R; Chan LC; Hinkel M; Martinez-Morilla S; Pignatelli J; Trapani F; Corse E; Feng D; Kostyrko K; Hofmann MH; Liu K; Kashyap AS
    Cancer Res Commun; 2024 Jun; 4(6):1548-1560. PubMed ID: 38727236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kras
    Cheng H; Fan K; Luo G; Fan Z; Yang C; Huang Q; Jin K; Xu J; Yu X; Liu C
    Cancer Lett; 2019 Apr; 446():103-111. PubMed ID: 30664964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P21 activated kinase signaling in cancer.
    Rane CK; Minden A
    Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Critical role of oncogenic KRAS in pancreatic cancer (Review).
    Liu J; Ji S; Liang C; Qin Y; Jin K; Liang D; Xu W; Shi S; Zhang B; Liu L; Liu C; Xu J; Ni Q; Yu X
    Mol Med Rep; 2016 Jun; 13(6):4943-9. PubMed ID: 27121414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting integrin-linked kinase to suppress oncogenic KRAS signaling in pancreatic cancer.
    Chu PC; Kulp SK; Bekaii-Saab T; Chen CS
    Small GTPases; 2018 Nov; 9(6):452-456. PubMed ID: 27936345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changing the course of pancreatic cancer--Focus on recent translational advances.
    Javle M; Golan T; Maitra A
    Cancer Treat Rev; 2016 Mar; 44():17-25. PubMed ID: 26924195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
    Pettazzoni P; Viale A; Shah P; Carugo A; Ying H; Wang H; Genovese G; Seth S; Minelli R; Green T; Huang-Hobbs E; Corti D; Sanchez N; Nezi L; Marchesini M; Kapoor A; Yao W; Francesco ME; Petrocchi A; Deem AK; Scott K; Colla S; Mills GB; Fleming JB; Heffernan TP; Jones P; Toniatti C; DePinho RA; Draetta GF
    Cancer Res; 2015 Mar; 75(6):1091-101. PubMed ID: 25736685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune modulatory effects of oncogenic KRAS in cancer.
    Hamarsheh S; Groß O; Brummer T; Zeiser R
    Nat Commun; 2020 Oct; 11(1):5439. PubMed ID: 33116132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hope on the Horizon: A Revolution in KRAS Inhibition Is Creating a New Treatment Paradigm for Patients with Pancreatic Cancer.
    Aguirre AJ; Stanger BZ; Maitra A
    Cancer Res; 2024 Sep; 84(18):2950-2953. PubMed ID: 39279379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Group II p21-activated kinases as therapeutic targets in gastrointestinal cancer.
    Shao YG; Ning K; Li F
    World J Gastroenterol; 2016 Jan; 22(3):1224-35. PubMed ID: 26811660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.